At present, they have 15 molecules in development phase and 21 in commercial phase ( not counting 51 molecules combined in Phase-1,2,3 and pre-clinical stages ). Greater clarity on these 36 molecules ( development + commercial ) wrt their revenue potential in the concall shall be the thing to watch out for.
If the management guidance is upbeat, Neuland may be in for a re-rating.
| Subscribe To Our Free Newsletter |
